Next Article in Journal
Impedance Cardiography and Heart Rate Variability for Long-Term Cardiovascular Outcome Prediction After Myocardial Infarction
Previous Article in Journal
Recent Advances in Endovascular Treatment of Aortoiliac Occlusive Disease
Medicina is published by MDPI from Volume 54 Issue 1 (2018). Articles in this Issue were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence. Articles are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Lithuanian Medical Association, Lithuanian University of Health Sciences, and Vilnius University.
Open AccessArticle

Associations Between TFPI-2 Methylation and Poor Prognosis in Glioblastomas Paulina Vaitkienė, Daina Skiriutė, Kęstutis Skauminas

Laboratory of Neurooncology and Genetics, Neuroscience Institute, Medical Academy, Lithuanian University of Health Sciences, Lithuania
*
Author to whom correspondence should be addressed.
Medicina 2012, 48(7), 51; https://doi.org/10.3390/medicina48070051
Received: 5 March 2012 / Accepted: 30 July 2012 / Published: 4 August 2012
Background and Objective. The epigenetic silencing of tumor suppressor genes plays an important role in gliomagenesis. Recently, tissue factor pathway inhibitor 2 (TFPI-2) has been suggested as a tumor suppressor gene involved in tumorigenesis and metastasis in some cancers. However, to date, little is known about the methylation status of TFPI-2 gene in glioblastoma tissues. In this study, we aimed to investigate the methylation status of TFPI-2 promoter and its associations with patient prognosis in glioblastoma.
Material and Methods
. The methylation status of TFPI-2 was investigated by methylationspecific polymerase chain reaction in 99 glioblastoma patients. The associations between patients’ clinical variables and overall survival time were assessed.
Results
. TFPI-2 was aberrantly methylated in 22.2% (22/99) of glioblastoma tumors, but was not methylated in normal brain samples. The survival of patients with glioblastoma differed significantly between the methylated and unmethylated TFPI-2 groups (P=0.047). The 2-year survival among patients carrying methylated TFPI-2 tumors was significantly lower compared with that of patients with unmethylated TFPI-2 (27% versus 4.7%, P=0.037).
Conclusions
. The present work demonstrated that the epigenetic inactivation of TFPI-2 by promoter hypermethylation was a frequent and tumor-specific event in glioblastoma, and TFPI-2 promoter methylation might be considered as a prognostic marker in glioblastoma.
Keywords: glioblastoma; tissue factor pathway inhibitor 2; methylation; survival glioblastoma; tissue factor pathway inhibitor 2; methylation; survival
MDPI and ACS Style

Vaitkienė, P.; Skiriutė, D.; Skauminas, K.; Tamašauskas, A. Associations Between TFPI-2 Methylation and Poor Prognosis in Glioblastomas Paulina Vaitkienė, Daina Skiriutė, Kęstutis Skauminas. Medicina 2012, 48, 51.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Back to TopTop